Statin and beta-blocker therapy and the initial presentation of coronary heart disease
Alan S Go1, Carlos Iribarren, Malini Chandra
1Division of Research, Kaiser Permanente of Northern California, Oakland, California 94612-2304, USA. Alan.S.Go@kp.org
Insights
Statin and beta-blocker use was linked to fewer acute myocardial infarction (heart attack) cases compared to stable angina. These findings suggest potential protective effects against severe coronary disease presentations.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Coronary atherosclerosis is a chronic condition often presenting as sudden, unstable events like acute myocardial infarction (AMI).
- Patients with AMI may differ significantly from those with stable exertional angina.
Purpose of the Study:
- To investigate if patient characteristics or medication use influence the initial clinical presentation of coronary artery disease.
- To compare factors associated with acute myocardial infarction versus stable exertional angina.
Main Methods:
- A case-control study was conducted within a large healthcare system.
- Included adults with initial presentations of either AMI (n=916) or stable exertional angina (n=468).
- Data on cardiac medication use, demographics, lifestyle, and clinical factors were collected.
Main Results:
- Patients with AMI were more likely to be male, smokers, inactive, and hypertensive, but less likely to have a family history of coronary disease.
- AMI patients were significantly less likely to have used statins (19.3%) or beta-blockers (19.0%) compared to exertional angina patients (40.4% and 47.7%, respectively).
- Statin and beta-blocker use were associated with reduced odds of presenting with AMI versus stable angina.
Conclusions:
- Statin and beta-blocker use correlated with a lower likelihood of experiencing an acute myocardial infarction as the initial presentation.
- Further research is required to confirm the protective role of these medications against severe coronary disease events.
- Limitations include potential unmeasured confounding factors, such as aspirin use.
Background:
Coronary atherosclerosis develops slowly over decades but is frequently characterized clinically by sudden unstable episodes. Patients who present with unstable coronary disease, such as acute myocardial infarction, may systematically differ from patients who present with relatively stable coronary disease, such as exertional angina.
Objective:
To examine whether medication use or patient characteristics influence the mode of initial clinical presentation of coronary disease.
Design:
Case-control study.
Setting:
Large integrated health care delivery system in northern California.
Patients:
Adults whose first clinical presentation of coronary disease was either acute myocardial infarction (n = 916) or stable exertional angina (n = 468).
Measurements:
Use of cardiac medications before the event from pharmacy databases and demographic, lifestyle, and clinical characteristics from self-report and clinical and administrative databases.
Results:
Compared with patients with incident stable exertional angina, patients with incident acute myocardial infarction were more likely to be men, smokers, physically inactive, and hypertensive but were less likely to have a parental history of coronary disease. Patients presenting with myocardial infarction were much less likely to have received statins (19.3% vs. 40.4%; P < 0.001) and beta-blockers (19.0% vs. 47.7%; P < 0.001) than patients presenting with exertional angina. After adjustment for potential confounders, recent use of statins (adjusted odds ratio, 0.45 [95% CI, 0.32 to 0.62]) and beta-blockers (adjusted odds ratio, 0.26 [CI, 0.19 to 0.35]) was associated with lower likelihoods of presenting with an acute myocardial infarction than with stable angina.
Limitations:
This observational study did not have information on all possible confounding factors, including use of aspirin therapy.
Conclusion:
Statin and beta-blocker use was associated with lower odds of presenting with an acute myocardial infarction than with stable angina. Additional studies are needed to confirm that these therapies protect against unstable, higher-risk clinical presentations of coronary disease.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management